Wedbush Boosts Earnings Estimates for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. (TSE:FRX) – Analysts at Wedbush raised their Q4 2024 earnings estimates for Fennec Pharmaceuticals in a research note issued to investors on Sunday, December 22nd. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will earn $1.88 per share for the quarter, up from their previous estimate of ($0.24). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.16) EPS, Q4 2025 earnings at $0.66 EPS and FY2025 earnings at $0.66 EPS.

Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Stock Performance

Shares of Fennec Pharmaceuticals stock opened at C$8.93 on Wednesday. The stock’s fifty day simple moving average is C$7.25 and its 200 day simple moving average is C$7.67. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68. The company has a market capitalization of C$244.32 million, a PE ratio of 89.30 and a beta of 0.25. Fennec Pharmaceuticals has a 12 month low of C$5.65 and a 12 month high of C$15.43.

Insiders Place Their Bets

In other news, Director Rostislav Christov Raykov purchased 25,000 shares of Fennec Pharmaceuticals stock in a transaction on Friday, December 20th. The stock was purchased at an average price of C$3.87 per share, with a total value of C$96,840.00. Also, Senior Officer Robert Christopher Andrade acquired 15,816 shares of the stock in a transaction dated Monday, November 18th. The stock was acquired at an average price of C$3.43 per share, for a total transaction of C$54,248.88. In the last three months, insiders have purchased 41,612 shares of company stock worth $157,868. Company insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.